J&J Nevo Stent Inhibits Tissue Proliferation Better Than Boston Sci’s Liberté

Johnson & Johnson/Cordis' Nevo next-generation sirolimus-eluting coronary stent inhibits tissue proliferation better than Boston Scientific's Taxus Liberté paclitaxel-eluting stent at six months, according to data from the NEVO RES-Elution I study unveiled May 19 at the EuroPCR meeting in Barcelona